knowledge -WSS

knowledge

author：knowledge 2025-08-22 20:55:19 - browse：94637

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Healthy food access boosts outcomes in two studies

explore

knowledge

WSS

Chinese researcher claims birth of first gene

Healthy food access boosts outcomes in two studies

After decades in use, heart stents finally beat placebo

'Patient friction coefficient' can gauge a clinical trial's patient burden

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

UnitedHealth sued over use of algorithm in Medicare Advantage plans

knowledge

knowledge

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Cancer diagnosis changes perspective doctor, former hospital CEO

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

DIEP, the 'gold standard' of breast reconstruction, is under threat

Adam's Take: Intra

Alkermes shareholders re

U.K. officials, researchers try to ease path for bespoke genetic treatments

Cancer drug shortages should be causing more outrage

Medical school prerequisites are outdated

focus

Adam's Take: Intra

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Experimental asthma app from Apple and Anthem shows promise

Today's health inequities arise from racist U.S. history, say experts

Weight loss drugs should be covered by insurers, AMA says

Mirador, a new biotech startup, launches with $400 million

explore

Wikipedia

knowledge

entertainment